Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer. | Synapse
March 2, 2026
Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer.
Key Points
To assess the toxicity and clinical effectiveness of the combination of binimetinib and hydroxychloroquine in patients with advanced pancreatic cancer.
Conducted a Phase I clinical trial
Involved patients with metastatic pancreatic cancer who had received previous treatment
Evaluated the combination treatment for toxicity and clinical responses
The combination treatment showed a challenging toxicity profile
Limited clinical activity was observed in patients
Many patients were classified as chemorefractory, limiting effectiveness
Abstract
The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.